Get the Stockscreener App
29.89
0.10%
-0.03
After Hours:
29.76
-0.13
-0.43%
Moderna Inc stock is traded at $29.89, with a volume of 7.35M.
It is down -0.10% in the last 24 hours and up +20.67% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$29.92
Open:
$29.91
24h Volume:
7.35M
Relative Volume:
0.68
Market Cap:
$11.68B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.4238
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+5.84%
1M Performance:
+20.67%
6M Performance:
+14.96%
1Y Performance:
-28.56%
1-Day Range:
$29.04
$30.00
1-Week Range:
$27.98
$30.43
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
29.89 | 11.69B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike - Yahoo Finance
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Erie Times-News
Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE VaccineHas The Bull Case Changed? - Yahoo Finance
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Coshocton Tribune
XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire Inc.
Moderna Options Trading: A Deep Dive into Market Sentiment - Benzinga
Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders - GuruFocus
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells 23,853 Shares of Stock - MarketBeat
Noubar Afeyan, Moderna director, sells $703k in MRNA stock - Investing.com
Chmn Afeyan Sells 23,853 ($703.3K) Of Moderna Inc [MRNA] - TradingView — Track All Markets
Moderna’s new COVID vaccine receives positive CHMP opinion By Investing.com - Investing.com India
Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine - GuruFocus
Moderna’s new COVID vaccine receives positive CHMP opinion - Investing.com
Moderna (NASDAQ: MRNA) COVID shot mNEXSPIKE backed by EMA panel for EU nod - Stock Titan
Big COVID-19 Vaccine Update: Pfizer, Moderna Nearing Finish Line - cbn.com
Moderna on track to extend gains for the seventh straight trading day - MSN
Telemark Asset Management, LLC's Moderna Inc(MRNA) Holding History - GuruFocus
Moderna to Host Investor Event – Analyst Day - York Dispatch
Bellevue Group AG Has $34.18 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Banque Transatlantique SA Cuts Position in Moderna, Inc. $MRNA - MarketBeat
PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts - TipRanks
Moderna (NASDAQ:MRNA) Director Sells $13,910.40 in Stock - MarketBeat
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says - Proactive financial news
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Morningstar
ImmunityBio, Moderna among winners of EU drug recommendations this week - Seeking Alpha
EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike - TradingView
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges - GuruFocus
Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating - marketscreener.com
MRNA: Jefferies Initiates Coverage with Hold Rating and $30 PT | - GuruFocus
Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target - marketscreener.com
Moderna signs deal worth up to $503m with Nanexa - Pharmaceutical Technology
Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell - TradingView — Track All Markets
Jefferies initiates Moderna stock with Hold rating, $30 price target - Investing.com
Moderna Stock On Fire: Up 23% With 7-Day Winning Streak - Trefis
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? - Stocktwits
Petition claims FDA oops! means COVID-19 vaccines misbranded - BioWorld MedTech
Moderna protects you from illness and poor vaccine information - WSBT
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.? - GuruFocus
Moderna (MRNA) Q1 2025 Earnings Call Transcript - The Globe and Mail
Covid Shots Slash ER Visits for Kids in CDC Study - Bloomberg.com
Is the Market Bullish or Bearish on Moderna Inc? - Benzinga
Moderna and Super Micro top S&P 500 short interest list — are they ripe for a squeeze? - MSN
Moderna Secures $1.5B Five-Year Loan from Ares Management Ahead of Strategy Update - Finviz
US in "big danger" of falling behind in vaccine tech amid funding cuts, skepticism: Moderna co-founder - Seeking Alpha
Moderna Founder Warns US Doubts on Science Threaten Biotech Edge - Bloomberg.com
Moderna Stock Rockets 21% With 6-Day Winning Streak - Trefis
Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products - TradingView — Track All Markets
Researchers Identify Immune Trigger Behind Myocarditis After Covid Vaccination - Bloomberg.com
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Ames Tribune
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Livingston Daily
First Trust Advisors LP Has $34.02 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):